Dossier assessment
Indicaterol/glycopyrronium - Benefit assessment according to § 35a Social Code Book V (dossier assessment)
Report documents
-
Extract of dossier assessment
Indicaterol/glycopyrronium - Benefit assessment according to § 35a Social Code Book V (dossier assessment)
-
Dossier assessment
Indicaterol/glycopyrronium - Benefit assessment according to § 35a Social Code Book V (dossier assessment)
Press releases
Minor added benefit of indacaterol/glycopyrronium in COPD
Fewer breathing difficulties in moderate severity grades / no data for patients at later stages of disease
Additional information
Federal Joint Committee (G-BA)
2014-05-08 A G-BA decision was published.
Project details
- Project no.
- A13-40
- Commission
- Commission awarded on 06.11.2013 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Airways and respiratory system
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.